Dose-Specific Packaging for Lenvatinib in Endometrial Cancer Could Improve Adherence, But Drives Overspending
Lenvatinib was approved in July of 2021 for the treatment of microsatellite-stable advanced endometrial cancer after platinum-based chemotherapy.
In an interview with Pharmacy Times, Emeline Aviki, MD, discussed research presented at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer regarding dose-specific packaging in lenvatinib.
In part 1 of the discussion, Aviki said lenvatinib was approved in July of 2021 for the treatment of microsatellite-stable advanced endometrial cancer after platinum-based chemotherapy. Dose-specific packaging is often used with lenvatinib because it is believed to improve adherence, but Aviki said that it can also lead to overspending when patients are prescribed dose-reductions before finishing the 30-day prescription.
